Dosage Charts Calculator Blends & Stacks Learn Blog Peptides
Open Calculator
Blog  ›  Thymosin Alpha-1 vs Thymalin: Simple Research Comparison

Thymosin Alpha-1 vs Thymalin: Simple Research Comparison

Jun 11, 2026 4 min Immune
TL;DR
Thymosin Alpha-1 is a single, well-defined 28-amino-acid peptide with decades of published clinical trials behind it. Thymalin is a broader thymic extract mixture studied mainly in Eastern European aging and immune research. They share thymic roots but differ sharply in composition, research depth, and the doses used in studies.

Two Peptides, One Gland

Both Thymosin Alpha-1 and Thymalin come from the thymus — a small gland behind your breastbone that trains your immune cells. That shared origin is why people often confuse them. But they are quite different molecules with very different research histories.

What Is Thymosin Alpha-1?

Thymosin Alpha-1 (often written Tα1) is a single, precisely defined peptide made of 28 amino acids. Think of it as one specific tool from the thymus toolbox. Because its structure is known exactly, it can be manufactured synthetically, and researchers can run tightly controlled studies on it.

The research base is large. Studies have explored Tα1 in chronic hepatitis B, where it was shown to enhance T-cell response and suppress viral replication.[2] Other work covers HIV, sepsis, cancer, and aging.[3] In sepsis research, single or combined Tα1 treatment reduced mortality rates and improved immune markers like HLA-DR expression on monocytes.[5] Cancer researchers are excited because Tα1 stimulates both innate and adaptive immune responses and may enhance the effect of checkpoint inhibitor drugs.[6] There is even work on Tα1 slowing immunosenescence — that's the gradual wearing-down of your immune system as you age — by stimulating T-cell production and improving vaccine responses in older adults.[1]

In HIV research, Tα1 has been described as a "multitasking protein" that can help restore immune homeostasis when antiretroviral therapy alone leaves gaps.[4]

Typical Research Doses for Thymosin Alpha-1

Clinical trials have most commonly used 1.6 mg injected subcutaneously (just under the skin), typically twice a week. Some sepsis studies used daily dosing. Duration in trials ranges from a few weeks to several months depending on the condition studied.[3] Always use a calculator to understand how published doses translate to research contexts — never self-dose.

What Is Thymalin?

Thymalin is a thymic peptide extract — meaning it contains a mixture of small peptides isolated from calf thymus tissue, rather than one pure molecule. It was developed in the Soviet Union in the 1970s and has been studied primarily in Russia and Eastern Europe.

Because it is a mixture, its exact composition can vary. Research on Thymalin focuses heavily on aging, longevity, and age-related immune decline. Some studies report improvements in immune function and even survival metrics in elderly populations over long follow-up periods. It is typically administered by intramuscular injection.

Typical Research Doses for Thymalin

Studies have used doses in the range of 10–30 mg per course, often split over 5–10 daily injections, repeated periodically (for example, once or twice per year). The episodic, course-based dosing model is quite different from the steady twice-weekly schedule seen in Tα1 trials.

Quick Comparison at a Glance

  • Structure: Tα1 = single 28-amino-acid peptide; Thymalin = mixed thymic extract
  • Research volume: Tα1 has far more published international clinical trials
  • Main research areas: Tα1 — infections, cancer, sepsis, aging; Thymalin — aging, longevity, immune restoration
  • Typical study dose: Tα1 ≈ 1.6 mg twice weekly; Thymalin ≈ 10–30 mg per treatment course
  • Administration: Both injectable; Tα1 usually subcutaneous, Thymalin often intramuscular
  • Regulatory status: Tα1 approved in some countries for hepatitis B; Thymalin approved in Russia; neither widely approved in the US or EU

How to Choose What to Read About

Ask yourself what draws your curiosity. If you are interested in viral infections, cancer immunology, or sepsis, the Thymosin Alpha-1 literature is deep and internationally peer-reviewed.[3] If you are drawn to aging biology and longevity research, Thymalin's track record in that niche is worth exploring, keeping in mind that most of that data comes from a narrower geographic and institutional base.

For either peptide, understanding the exact doses used in the studies you are reading matters enormously. A calculator can help you make sense of the numbers you encounter in papers. See our full breakdowns on the Thymosin Alpha-1 and Thymalin chart pages for sourced dosing tables.

This article is for educational purposes only and does not constitute medical advice. These peptides are for research use only.

Sources

  1. Aging and Thymosin Alpha-1. — International journal of molecular sciences, 2025. PMID 41373628.
  2. Thymosin alpha-1 treatment in chronic hepatitis B. — Expert opinion on biological therapy, 2015. PMID 25640173.
  3. Thymosin alpha 1: A comprehensive review of the literature. — World journal of virology, 2020. PMID 33362999.
  4. Thymosin alpha 1 and HIV-1: recent advances and future perspectives. — Future microbiology, 2017. PMID 28106477.
  5. Thymosin alpha 1 treatment for patients with sepsis. — Expert opinion on biological therapy, 2018. PMID 30063866.
  6. Thymosin α-1 in cancer therapy: Immunoregulation and potential applications. — International immunopharmacology, 2023. PMID 36812669.
See the dosage chart — Thymosin Alpha-1
A thymic peptide studied for immune regulation.
Thymosin Alpha-1

FAQ

Are Thymosin Alpha-1 and Thymalin the same thing?
No. Thymosin Alpha-1 is a single, chemically defined 28-amino-acid peptide with a large body of international clinical research behind it. Thymalin is a mixed extract of multiple small peptides from thymus tissue, studied mainly in Eastern European aging research. They both originate from the thymus gland but are structurally and scientifically quite different.
What conditions has Thymosin Alpha-1 been studied for?
Research has examined Thymosin Alpha-1 across a wide range of areas including chronic hepatitis B, HIV, sepsis, various cancers, and age-related immune decline. Studies suggest it can stimulate T-cell activity, improve vaccine responses in elderly patients, and potentially enhance the effects of cancer immunotherapy drugs. All findings are from research settings, not personal medical recommendations.
What dose of Thymosin Alpha-1 is used in clinical studies?
The most common dose seen in published clinical trials is 1.6 mg injected subcutaneously, usually twice per week. Some sepsis protocols used daily dosing. Study durations vary widely. These are research doses from published papers — not personal dosing guidance. Always review the original studies and use a research calculator to understand the numbers in context.
Why does Thymalin have less published research than Thymosin Alpha-1?
Thymalin was developed in the Soviet Union and most studies were conducted in Russia and Eastern Europe, meaning much of the literature is in Russian and less represented in major international databases. Thymosin Alpha-1, by contrast, has been studied globally and is subject to extensive English-language peer review, giving it a much larger and more accessible published evidence base.
For research and educational use only. Not medical advice.